Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of ECC4703 With Sulfasalazine and Pitavastatin
Sponsor: Eccogene
Summary
Non-alcoholic fatty liver disease is a chronic, serious, life-threatening, inflammatory liver disease characterized by increased liver fat content, inflammation, and progressive fibrosis. The overall prevalence of non-alcoholic fatty liver disease is rapidly rising world-wide. ECC4703 is a potential new treatment for non-alcoholic fatty liver disease. The purpose of this research is to investigate the safety, tolerability and pharmacokinetics of sulfasalazine and pitavastatin when combined with ECC4703.
Official title: A Phase 1, Open-Label, Fixed-Sequence, Single-Center, Two-Period, Drug-Drug Interaction Trial in Healthy Adult Participants to Evaluate the Effect of Steady-State ECC4703 on the Pharmacokinetics of Sulfasalazine (BCRP Probe Substrate) and Pitavastatin (OATP1B1/OATP1B3 Probe Substrate)
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-08-07
Completion Date
2026-12
Last Updated
2026-09-10
Healthy Volunteers
Yes
Interventions
ECC4703
ECC4703 will be administered orally.
Sulfasalazine
Sulfasalazine will be administered orally.
Pitavastatin
Pitavastatin will be administered orally.
Locations (1)
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia